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Figure 1. Survival among patients alive at 90 days after transplant according
to whether they were admitted to the ICU within 90 days after transplant.
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survivors warrant validation in a larger cohort and further
research to understand its mechanism and develop
appropriate strategies. Our study is limited by type II and
type I errors due to small sample size and multiple variables.
Nonetheless, these results provide potentially important
data for patient counseling andmay help guide management
of critical illness post-transplant.354
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Background: In 2011, the American Society of Clinical
Oncology (ASCO) and the Oncology Nursing Society (ONS)
expanded the scope of their 2009 guidelines to address
chemotherapy administration safety in the inpatient setting
(Jacobson, J., Polovich, M., et al., 2012). The guidelines
encompass physician, pharmacy and nursing practices sur-
rounding chemotherapy ordering, processing and delivery. A
review of our current processes elucidated opportunity for
improvement.
Objectives: To develop and implement processes promoting
multidisciplinary congruency with the ASCO/ONS guidelines
across our BMT, Hematology and Oncology Inpatient and
Ambulatory Care units.
To safeguard administration of chemotherapy.
Interventions: Our initial step involved updating our
chemotherapy administration policy for pharmacy and
nursing to include recommendations from ONS/ASCO. The
policy underwent multiple revisions by nursing, pharmacy
and the medical staff prior to approval in July, 2013. Once
approved, we developed a checklist for both pharmacy and
nursing use to help ensure all required elements were
addressed in the order sets prior to processing a chemo-
therapy order. A separate checklist was created for RN use
before and after chemotherapy administration. Finally, we
revised the chemotherapy order template for physicians to
use in the absence of a pre-printed order set. RN staff,
oncology pharmacists and the oncologists were in-serviced
on the new policy, order sets and checklists. Beginning in
September, 2013, audits were performed on all returned
checklists.Evaluation: In the ﬁrst months following implementation
of the policy, compliance with completion of the checklists
was less than 50%. RN champions agreed to audit 100% of
the chemotherapy doses ordered and administered.
Pharmacy and Nursing compared their orders for the
month to ensure there were no missing checklists.
Compliance data was shared with the staff on the Oncology/
Blood Cancer/BMT Units and individual performance
deﬁcits were addressed. Audits of all orders and
checklists were continued until greater than 90% compliance
was reached. Audits are now done quarterly to monitor
continued compliance.355
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With changing immunomodulation, prophylactic and
empiric therapy in HSCT patients, continual reassessment of
infecting pathogens and rates of recovery are required as
infections remain a leading cause of morbidity andmortality.
We performed a retrospective chart review of 86 BMT
patients who underwent allogeneic HSCT (AlloSCT) or
autologous HSCT (ASCT) from 7/11 to 4/14 and with 100 days
of post-transplant follow-up. Evaluation included pathogen
detection and recovery from D0-30 and D31-100 (deﬁned as
one set of testing per 24h period).
Therewere 86 patients, 30 AlloSCT (median age 35, 20-66)
and 56 ASCT (median age 55, 20-72). Age and gender had no
statistically signiﬁcant effect on overall mortality. 100% of
patients underwent evaluations for infection. Of 406 total
samples obtained, only 22 (5%) revealed a pathogen. 158 (119
D0-30, 39 D31-100) blood culture evaluations were obtained
in 66 patients (50 D0-30, 16 D31-100) with only 10 (5 D0-30,
5 D31-100) positive evaluations in 8 patients. Overall, 11% of
ASCT and 14% of AlloSCT patients had clinically signiﬁcant
bacteremia. 96 (71 D0-30, 25 D31-100) urine cultures were
obtained in 55 patients with 3 (0 D0-30, 3 D31-100) positive
evaluations in 2 patients resulting in 0% of ASCT and 7% of
AlloSCT with clinically signiﬁcant bacteriuria. 152 (130
D0-30, 22 D31-100) C. diff tests were obtained in 77 patients
with 9 positive evaluations in 8 patients (6 D0-30, 2
D31-100) resulting in a C. diff detection rate of 12% and 11% in
ASCT and AlloSCT patients, respectively. All-cause mortality
was 14% (7% ASCT, 27% AlloSCT; p ¼ 0.021). Of patients with
positive blood, urine, and C.diff testing, mortality was 50% (p
¼ 0.020), 100% (p ¼ 0.042), and 25% (0.003), respectively. No
patients died during D0-D100. After D100, infection-related
mortality was 25%.
Actionable infections require rapid detection in BMT
patients. Clinical parameters often trigger extensive evalua-
tions but our diagnostic yield was < 15%. Infections during
D0-D100 were associated with greater all-cause mortality
and 25% of post-transplant death was attributed to infection.
While current empiric therapy has reduced infection rates,
improved clinical algorithms and methods of pathogen
detection are needed to improve HSCT care.
